Back to Search
ROBIN JUSTICE, PHARMD
PHARMD
Pharmacist
NPI: 1316378375Individual
Specialties, Licenses & Credentials
PharmacistPrimary
Pharmacist
Code: 183500000X
011430(KY)018422(GA)
Research & Publications (20)
Sorafenib for the treatment of unresectable hepatocellular carcinoma.
PMID 19144678·Oncologist·2009
6-review
Assessing proarrhythmic potential of drugs when optimal studies are infeasible.
PMID 19376308·Am Heart J·2009
6-review
Approval summary: imatinib mesylate in the treatment of metastatic and/or unresectable malignant gastrointestinal stromal tumors.
PMID 19193781·Oncologist·2009
3-trial
Tasigna for chronic and accelerated phase Philadelphia chromosome--positive chronic myelogenous leukemia resistant to or intolerant of imatinib.
PMID 18765523·Clin Cancer Res·2008
8-other
Sprycel for chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia resistant to or intolerant of imatinib mesylate.
PMID 18223208·Clin Cancer Res·2008
8-other
FDA drug approval summary: nelarabine (Arranon) for the treatment of T-cell lymphoblastic leukemia/lymphoma.
PMID 18586926·Oncologist·2008
8-other
Dexrazoxane (Totect): FDA review and approval for the treatment of accidental extravasation following intravenous anthracycline chemotherapy.
PMID 18448560·Oncologist·2008
8-other
Ixabepilone in combination with capecitabine and as monotherapy for treatment of advanced breast cancer refractory to previous chemotherapies.
PMID 18628451·Clin Cancer Res·2008
4-observational
Lenalidomide in combination with dexamethasone for the treatment of multiple myeloma after one prior therapy.
PMID 18922829·Oncologist·2008
4-observational
FDA drug approval summary: lapatinib in combination with capecitabine for previously treated metastatic breast cancer that overexpresses HER-2.
PMID 18849320·Oncologist·2008
3-trial
Approval summary: sunitinib for the treatment of imatinib refractory or intolerant gastrointestinal stromal tumors and advanced renal cell carcinoma.
PMID 17332278·Clin Cancer Res·2007
6-review
Erlotinib/gemcitabine for first-line treatment of locally advanced or metastatic adenocarcinoma of the pancreas.
PMID 18247017·Oncology (Williston Park)·2007
3-trial
Liposomal doxorubicin in combination with bortezomib for relapsed or refractory multiple myeloma.
PMID 18077994·Oncology (Williston Park)·2007
3-trial
FDA approval summary: vorinostat for treatment of advanced primary cutaneous T-cell lymphoma.
PMID 17962618·Oncologist·2007
3-trial
Hydrogen-bonded metal-complex sulfonate (MCS) inclusion compounds: effect of the guest molecule on the host framework.
PMID 17461580·Inorg Chem·2007
8-other
Vorinostat for treatment of cutaneous manifestations of advanced primary cutaneous T-cell lymphoma.
PMID 17438089·Clin Cancer Res·2007
7-preclinical
Food and Drug Administration drug approval summary: Sunitinib malate for the treatment of gastrointestinal stromal tumor and advanced renal cell carcinoma.
PMID 17227905·Oncologist·2007
8-other
Sorafenib for the treatment of advanced renal cell carcinoma.
PMID 17189398·Clin Cancer Res·2006
6-review
Topotecan in combination with cisplatin for the treatment of stage IVB, recurrent, or persistent cervical cancer.
PMID 17112001·Oncology (Williston Park)·2006
4-observational
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Contact & Hours
- Address
- 160 CONN STREET, SUITE 2
IVEL, KY 41642 - Phone
- (606) 478-3784
Quick Facts
- NPI
- 1316378375
- Entity Type
- Individual
- Gender
- Female
- Medicare
- Not confirmed
- Specialties
- 2
- Locations
- 1
- Publications
- 20
Are you this provider?
Claim Your Profile